Although the paradigmatic combined therapy of ATRA and As2O3 have benefited most patients with APL to be definitively cured, rare cases of APL with fusion genes other than PML-RARα still exist with molecular pathogenesis remaining largely unclear. This evidence concerns the gene RARA and acute promyelocytic leukemia.